• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

撤回:激素替代疗法、依替膦酸二钠、降钙素、阿法骨化醇和维生素K在绝经后骨质疏松症女性中的比较疗效:山口骨质疏松预防研究。

RETRACTED: Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study.

作者信息

Ishida Yoichiro, Kawai Shinya

机构信息

Department of Orthopedic Surgery, Yamaguchi University School of Medicine, Ube-City, Japan.

出版信息

Am J Med. 2004 Oct 15;117(8):549-55. doi: 10.1016/j.amjmed.2004.05.019.

DOI:10.1016/j.amjmed.2004.05.019
PMID:15465502
Abstract

This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of the Editor in Chief because of the stated concerns listed below. This article was accepted for publication by a previous editor and editorial board, at a time when submissions and documentation were in paper form, prior to the transition of The American Journal of Medicine to a digital submission and review process. These records are no longer extant and consequently we are unable to review the comments of the reviewers and editors involved at that time. We have attempted to contact the authors regarding these concerns and received no response. We are therefore retracting this article since the evidence presented below strongly argues for scientific misconduct. The integrity of these publications is severely compromised by wide-ranging and serious concerns about governance, ethics, authorship, implausible study conduct, implausible workload, discrepant participant numbers and treatment groups, impossible data, implausible data, implausible outcome data, and discrepant methodology.

摘要

本文已被撤回

请参阅爱思唯尔的文章撤回政策(https://www.elsevier.com/about/our-business/policies/article-withdrawal)。由于以下所述的问题,本文应主编要求被撤回。本文在《美国医学杂志》向数字投稿和评审流程过渡之前,由前任编辑和编辑委员会接受发表,当时投稿和文档均为纸质形式。这些记录现已不存在,因此我们无法查看当时参与评审的审稿人和编辑的意见。我们已就这些问题试图联系作者,但未得到回复。鉴于以下提出的证据强烈表明存在科研不端行为,我们因此撤回本文。这些出版物的完整性因在治理、伦理、作者身份、不合理的研究行为、不合理的工作量、不一致的参与者数量和治疗组、不可能的数据、不合理的数据、不合理的结果数据以及不一致的方法学等方面存在广泛而严重的问题而受到严重损害。

相似文献

1
RETRACTED: Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study.撤回:激素替代疗法、依替膦酸二钠、降钙素、阿法骨化醇和维生素K在绝经后骨质疏松症女性中的比较疗效:山口骨质疏松预防研究。
Am J Med. 2004 Oct 15;117(8):549-55. doi: 10.1016/j.amjmed.2004.05.019.
2
RETRACTED: Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease.撤回:同型半胱氨酸作为帕金森病老年女性髋部骨折的预测因素。
Am J Med. 2005 Nov;118(11):1250-5. doi: 10.1016/j.amjmed.2005.01.052.
3
RETRACTED: Beneficial effect of etidronate therapy in chronically hospitalized, disabled patients with stroke.撤稿:依替膦酸二钠治疗慢性住院残疾脑卒中患者的有益作用。
J Stroke Cerebrovasc Dis. 2010 May;19(3):198-203. doi: 10.1016/j.jstrokecerebrovasdis.2009.04.006.
4
[Indications and limitations of non-hormonal treatments of osteoporosis].[骨质疏松症非激素治疗的适应证与局限性]
Rev Fr Gynecol Obstet. 1993 Jul-Sep;88(7-9):419-23.
5
RETRACTED: An open-label trial comparing alendronate and alphacalcidol in reducing falls and hip fractures in disabled stroke patients.撤稿声明:一项比较阿仑膦酸钠和阿尔法骨化醇在减少残疾脑卒中患者跌倒和髋部骨折的开放性标签试验。
J Stroke Cerebrovasc Dis. 2011 Jan-Feb;20(1):41-46. doi: 10.1016/j.jstrokecerebrovasdis.2009.10.007. Epub 2010 Jul 3.
6
Effects of 5-year treatment with elcatonin and alfacalcidol on lumbar bone mineral density and the incidence of vertebral fractures in postmenopausal women with osteoporosis: a retrospective study.依降钙素和阿法骨化醇5年治疗对绝经后骨质疏松症女性腰椎骨密度及椎体骨折发生率的影响:一项回顾性研究
J Orthop Sci. 2002;7(6):637-43. doi: 10.1007/s007760200114.
7
A comparison of the effectiveness and cost of treatment for vertebral fractures in women.女性椎体骨折治疗的有效性与成本比较。
Br J Rheumatol. 1995 Dec;34(12):1167-71. doi: 10.1093/rheumatology/34.12.1167.
8
RETRACTED: Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes.撤回:阿仑膦酸钠治疗绝经后骨质疏松症合并或不合并 2 型糖尿病日本女性患者的 3 年经验。
Diabetes Res Clin Pract. 2011 Aug;93(2):166-173. doi: 10.1016/j.diabres.2011.03.033. Epub 2011 Apr 27.
9
Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.依替膦酸二钠用于绝经后妇女骨质疏松性骨折的一级和二级预防。
Cochrane Database Syst Rev. 2008 Jan 23;2008(1):CD003376. doi: 10.1002/14651858.CD003376.pub3.
10
A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.一项针对绝经后骨质疏松症女性的为期四年的随机对照试验,该试验涉及单独使用或联合使用激素替代疗法和双膦酸盐。
Am J Med. 1998 Mar;104(3):219-26. doi: 10.1016/s0002-9343(98)00029-1.

引用本文的文献

1
Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.依替膦酸二钠用于绝经后妇女骨质疏松性骨折的一级和二级预防。
Cochrane Database Syst Rev. 2024 Apr 9;4(4):CD003376. doi: 10.1002/14651858.CD003376.pub4.
2
Vitamin K supplementation and bone mineral density in dialysis: results of the double-blind, randomized, placebo-controlled RenaKvit trial.透析患者的维生素 K 补充与骨矿物质密度:双盲、随机、安慰剂对照的 RenaKvit 试验结果。
Nephrol Dial Transplant. 2023 Sep 29;38(10):2131-2142. doi: 10.1093/ndt/gfac315.
3
Efficacy and safety of vitamin K2 for postmenopausal women with osteoporosis at a long-term follow-up: meta-analysis and systematic review.
维生素 K2 对长期随访的绝经后骨质疏松症妇女的疗效和安全性:荟萃分析和系统评价。
J Bone Miner Metab. 2022 Sep;40(5):763-772. doi: 10.1007/s00774-022-01342-6. Epub 2022 Jun 16.
4
Effect of Vitamin K on Bone Mineral Density and Fracture Risk in Adults: Systematic Review and Meta-Analysis.维生素K对成年人骨密度和骨折风险的影响:系统评价与荟萃分析
Biomedicines. 2022 May 1;10(5):1048. doi: 10.3390/biomedicines10051048.
5
Pharmacological Therapies for Osteoporosis: A Bayesian Network Meta-Analysis.骨质疏松症的药物治疗:一项贝叶斯网络荟萃分析。
Med Sci Monit. 2022 Apr 17;28:e935491. doi: 10.12659/MSM.935491.
6
Calcitonin: A useful old friend.降钙素:一位有用的老朋友。
J Musculoskelet Neuronal Interact. 2020 Dec 1;20(4):600-609.
7
Vitamin K and Osteoporosis.维生素 K 与骨质疏松症。
Nutrients. 2020 Nov 25;12(12):3625. doi: 10.3390/nu12123625.
8
Molecular Mechanisms and Emerging Therapeutics for Osteoporosis.骨质疏松症的分子机制与新兴治疗策略。
Int J Mol Sci. 2020 Oct 15;21(20):7623. doi: 10.3390/ijms21207623.
9
Beneficial Effects of Vitamin K Status on Glycemic Regulation and Diabetes Mellitus: A Mini-Review.维生素 K 状态对血糖调节和糖尿病的有益影响:小型综述。
Nutrients. 2020 Aug 18;12(8):2485. doi: 10.3390/nu12082485.
10
Comparison of the Anabolic Effects of Reported Osteogenic Compounds on Human Mesenchymal Progenitor-derived Osteoblasts.已报道的成骨化合物对人骨髓间充质祖细胞来源的成骨细胞的合成代谢作用比较。
Bioengineering (Basel). 2020 Jan 21;7(1):12. doi: 10.3390/bioengineering7010012.